Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME

Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME

Abstract Management of vitreoretinal disorders (e.g., neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) have assumed the standard therapy of lifelong anti-VEGF injections with drugs like aflibercept, brolucizumab, ranibizumab and bevacizumab. However, the burden i...

Full description

Bibliographic Details
Main Authors: Fernando M Penha, Maliha Masud, Zoha A. Khanani, Mathew Thomas, Rodney D. Fong, Kyler Smith, Avishay Chand, Majid Khan, Greggory Gahn, Gustavo Barreto Melo, Arshad M. Khanani
Format: Article
Language:English
Published: BMC 2024-01-01
Series:International Journal of Retina and Vitreous
Subjects:
Anti-VEGF-A
Angiopoietin 2
Neovascular age-related macular degeneration
Diabetic macular edema
Faricimab
Aflibercept
Online Access:https://doi.org/10.1186/s40942-024-00525-9

Internet

https://doi.org/10.1186/s40942-024-00525-9

Similar Items